



Committed to safer use of medicines worldwide

## ISO P Mid-Year Symposium 2023

1-2 June 2023, Leiden, Netherlands (Rijksmuseum Boerhaave)

*Pharmacovigilance: where science meets clinical practice*

### Programme

(Version 20230316)

Day 1- Thursday, June 1		
The role of clinical pharmacology, pharmacoepidemiology and pharmacovigilance in collecting and analysing safety information		
Session	Session title	Speaker
08.30-09.00	Registration	
Session 1 09.00-10.30	How can Pharmacovigilance, Epidemiology and Clinical Pharmacology collaborate to decrease harm of medicines? Chair: Linda Härmark	
09.00-09.10	Welcome and Introduction	
25'	Synergy between PV-CP-EPI from a clinical pharmacological perspective	Gerard Rongen <i>European Association for Clinical Pharmacology and Therapeutics (EACPT)</i>
25'	The synergy between PV-CP-EPI from an epidemiological perspective	Tobias Gerhard <i>International Society for Pharmacoepidemiology (ISPE)</i>

25'	The synergy between PV-CP-EPI from a Pharmacovigilance perspective	Daniel Morales Leaver <i>(EMA)</i>
15'	Panel discussion	
<i>10.30-11.00</i>	<i>Coffee Break and networking</i>	
Session 2 11.00-12.30	Do we need to re-think the concept of causality? Chair: Rebecca Chandler	
30'	Causality on group and individual level, how does it relates?	Eugene van Puijenbroek <i>The Netherlands Pharmacovigilance Centre Lareb</i>
30'	Dispositions and Causality Assessment in Pharmacovigilance	Elena Rocca <i>Oslo Met University</i>
30'	Panel discussion	
<i>12.30-13.30</i>	<i>Lunch</i>	
Session 3 13.30-15.00	Using information from other sources in PV Chair:	
30' or 25'	The use of real world evidence in pharmacovigilance	Helga Gardarsdottir <i>Utrecht University (Netherlands)</i>
30' or 25'	Detection of adverse drug reactions using hospital discharge database	Jean-Luc Faillie <i>CHU Montpellier, Montpellier University, Faculty of Medicine (France)</i>
30' or 25'	Title TBC	Charlotte James <i>MHRA (UK)</i>
2x7 mins	Abstract presentations	
<i>15.00-15.30</i>	<i>Coffee Break and networking</i>	
Session 4 15.30-17.00	Innovative methods in PV Chair: Charlotte James	

30' or 25'	Knowledge integration for case assessment and prioritisation	Marco Tuccori <i>University Hospital of Pisa (Italy)</i>
30' or 25'	Dealing with DPA in the post-Covid era	Sara Vidlin <i>Uppsala Monitoring Centre (Sweden)</i>
30' or 25'	Neural network, what is het and what are the possibilities in PV?	Andrew Bate <i>GSK (UK)</i>
2 x 7 mins	Abstract presentations	
17.00-18.00	European Chapter session	
<b>End of Day 1</b>		

<b>Day 2- Friday, June 2</b>		
<b>Implementing pharmacovigilance in clinical practice</b>		
	Welcome back and housekeeping	
Session 5 09.00-10.30	Implementing pharmacovigilance in clinical practice Chair: Francois Montastruc	
30'	Safety of JAK inhibitors	Christophe Richez <i>Bordeaux University (France)</i>
30'	Are ADRs predictable?	Henk-Jan Guchelaar <i>Leiden University Medical Center (Netherlands)</i>
30'	Using apps for communication between patient and HCP to monitor and manage ADRs	Corina van den Hurk <i>Netherlands Comprehensive Cancer Organisation (IKNL)</i>
10.30-11.00	<i>Coffee Break and networking</i>	
Session 6 11.00-12.30	The role of patients in PV Chair: Florence van Hunsel	
25'	Patient involvement in the safe use of drugs, CIOMS XI	Lembit Rägo <i>Council for International Organizations of Medical Sciences (CIOMS)</i>
25'	Role of patients in medicines safety monitoring: a perspective from the Patient and Consumer Working Party	Kasia Immonen <i>(EMA)</i>

25'	Engaging Patients via Online Healthcare Fora: Three Pharmacovigilance Use Cases	Vijay Kara <i>GSK (UK)</i>
2 x 7'	Abstract presentations	
12.30-13.30	<i>Lunch</i>	
Session 7 13.30-15.00	What do stakeholders need from PV? Chair: Agnes Kant	
25'	What do the general public need with regards to pharmacovigilance?	Maarten Keulemans <i>de Volkskrant</i>
25'	What do medical doctors need with regards to pharmacovigilance?	Teun van Gelder <i>Leiden University Medical Center (Netherlands)</i>
25'	What do patients need with regards to pharmacovigilance?	Rosa Castro <i>European Public Health Alliance (EPHA)</i>
15'	Panel discussion	
15.00-15.30	<i>Coffee Break and networking</i>	
Session 8 15.30-17.00	Science and practice, joining forces in PV Chair: Francesco Salvo	
25'	Science and practice, joining forces to moving PV forward, reflections from an epidemiological perspective	Toine Egberts <i>Utrecht University (Netherlands)</i>
25'	Science and practice, joining forces to moving PV forward, reflections from a clinical perspective	Rob van Marum <i>Jeroen Bosch hospital Center of expertise Clinical Pharmacology (Netherlands)</i>
25'	Science and practice, joining forces to moving PV forward, reflections from a pharmacovigilance perspective	Francois Montastruc <i>Faculty of Medicine and Toulouse University Hospital (France)</i>
15'	Panel discussion	
	Closing remarks	
End of the Symposium		